Tema Etfs LLC Makes New Investment in DexCom, Inc. (NASDAQ:DXCM)

Tema Etfs LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 28,643 shares of the medical device company's stock, valued at approximately $2,228,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Park Avenue Securities LLC boosted its position in DexCom by 13.9% during the 4th quarter. Park Avenue Securities LLC now owns 13,347 shares of the medical device company's stock valued at $1,038,000 after purchasing an additional 1,627 shares during the period. Hennion & Walsh Asset Management Inc. boosted its holdings in shares of DexCom by 17.1% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 5,163 shares of the medical device company's stock valued at $402,000 after acquiring an additional 754 shares during the period. Legacy Wealth Asset Management LLC bought a new position in shares of DexCom during the fourth quarter worth about $315,000. Carnegie Investment Counsel increased its holdings in shares of DexCom by 11.0% in the 4th quarter. Carnegie Investment Counsel now owns 3,530 shares of the medical device company's stock worth $275,000 after acquiring an additional 350 shares during the period. Finally, Avanza Fonder AB acquired a new stake in shares of DexCom in the 4th quarter worth about $3,731,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of analyst reports. Piper Sandler reduced their target price on shares of DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a research note on Friday, May 2nd. Mizuho assumed coverage on DexCom in a research report on Thursday, April 10th. They set an "outperform" rating and a $85.00 price objective for the company. Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research report on Saturday, March 8th. Robert W. Baird decreased their price target on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research note on Friday, May 2nd. Finally, Barclays raised their price target on DexCom from $90.00 to $93.00 and gave the company an "equal weight" rating in a report on Monday, May 5th. Five analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $98.00.

DexCom Stock Down 0.3%

NASDAQ:DXCM traded down $0.24 during trading hours on Friday, hitting $84.60. 633,767 shares of the company's stock traded hands, compared to its average volume of 4,346,532. The stock's fifty day moving average price is $73.26 and its two-hundred day moving average price is $78.02. The firm has a market cap of $33.17 billion, a P/E ratio of 59.09, a P/E/G ratio of 2.30 and a beta of 1.43. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $129.97.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share for the quarter, missing the consensus estimate of $0.33 by ($0.01). The business had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company's revenue was up 12.5% compared to the same quarter last year. During the same period last year, the firm earned $0.32 EPS. On average, research analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 14,076 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at $22,063,918.86. This trade represents a 4.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the sale, the chief executive officer now owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This represents a 8.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 66,926 shares of company stock worth $4,734,384 in the last quarter. 0.32% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.